KRYS Krystal Biotech, Inc.

NASDAQ
$315.34

Krystal Biotech, Inc. (KRYS) is expected to report earnings on February 1, 2027, before the market open. The consensus earnings estimate is $2.13 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.4% since its last earnings release on November 2, 2026.

Krystal Biotech Beat Consensus Estimates
Monday, November 2, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 1
Monday · 7:00 AM ET
Earnings Whisper
-
vs $2.13
Rev est $133.24M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $301.78

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Krystal Biotech, Inc.

Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.